Clinical Trial

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)

Study acronym: TOG-SAFRADJU
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 16, 2025 (before its estimated May 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to compare chemotherapy types that are given after surgery for biliary tract cancers. The main question it aims to answer is: Are any of the chemotherapy regimens more effective in preventing recurrence, providing longer survival, or having less toxicity? Nationwide multicenter retrospective data will be collected.
Trial Details
NCT Number NCT06975917
Lead Sponsor Ankara University
Collaborators: Turkish Oncology Group
Conditions Biliary Tract Cancer, Biliary Tract Cancers (BTC)
Enrollment 600 participants
Start Date 2024-11-01
Primary Completion 2025-05-30 (estimated)
Study Completion 2025-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-16